Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Qiagen ( (QGEN) ) has issued an update.
QIAGEN N.V. announced a synthetic share repurchase, consolidating every 36 shares into 35 as approved during the 2024 Annual General Meeting. This action affected the number of shares held by CC Verwaltungs GmbH, reducing it by 3,019 shares to a total of 105,637 common shares, reflecting a strategic move to optimize market positioning.
More about Qiagen
QIAGEN N.V. operates in the life sciences industry, focusing on providing products and services for molecular diagnostics and research. The company is known for its sample and assay technologies for molecular testing in clinical and industrial applications, serving global markets.
YTD Price Performance: -0.02%
Average Trading Volume: 949,621
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $9.69B
For a thorough assessment of QGEN stock, go to TipRanks’ Stock Analysis page.
